Related Experiment Video
Updated: Apr 6, 2026

Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis
Published on: January 31, 2025
Inhibition of hedgehog signaling reduces the side population in human malignant mesothelioma cell lines
11] Laboratory of Veterinary Clinical Pathology, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea [2] BK21 PLUS Program for Creative Veterinary Science Research, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.
Abstract:
Deregulation of crucial embryonic pathways, including hedgehog signaling, has been frequently implicated in a variety of human cancers and is emerging as an important target for anticancer therapy. This study evaluated the potential anticancer effects of cyclopamine, a chemical inhibitor of hedgehog signaling, in human malignant mesothelioma (HMM) cell lines. Cyclopamine treatment significantly decreased the proliferation of HMM cells by promoting apoptosis and shifting the cell cycle toward dormant phase. The clonogenicity and mobility of HMM cells were significantly decreased by cyclopamine treatment. Treatment of HMM cells with cyclopamine significantly reduced the abundance of side population cells, which were measured using an assay composed of Hoechst 33342 dye staining and subsequent flow cytometry. Furthermore, the expression levels of stemness-related genes were significantly affected by cyclopamine treatment. Taken together, the present study showed that targeting hedgehog signaling could reduce a more aggressive subpopulation of the cancer cells, suggesting an alternative approach for HMM therapy.
Insights
Cyclopamine, a hedgehog signaling inhibitor, reduced human malignant mesothelioma cell growth by inducing apoptosis and cell cycle arrest. This targeted therapy also decreased cancer stem cell populations, offering a novel approach for mesothelioma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Hedgehog signaling pathway deregulation is linked to various human cancers.
- This pathway is an emerging therapeutic target for anticancer strategies.
- Malignant mesothelioma (HMM) is an aggressive cancer with limited treatment options.
Purpose of the Study:
- To investigate the anticancer effects of cyclopamine, a hedgehog signaling inhibitor, on human malignant mesothelioma (HMM) cell lines.
- To determine if targeting hedgehog signaling can impact HMM cell proliferation, apoptosis, cell cycle, clonogenicity, mobility, and stemness characteristics.
Main Methods:
- Human malignant mesothelioma (HMM) cell lines were treated with cyclopamine.
- Cell proliferation, apoptosis, and cell cycle distribution were assessed.
- Clonogenicity and cell mobility assays were performed.
- Side population cells were identified and quantified using Hoechst 33342 dye staining and flow cytometry.
- Expression levels of stemness-related genes were analyzed.
Main Results:
- Cyclopamine significantly inhibited HMM cell proliferation.
- Treatment promoted apoptosis and induced cell cycle arrest in HMM cells.
- Clonogenicity and mobility of HMM cells were significantly reduced.
- Cyclopamine decreased the abundance of side population cells, indicative of cancer stem cells.
- Expression of stemness-related genes was significantly altered by cyclopamine treatment.
Conclusions:
- Targeting the hedgehog signaling pathway with cyclopamine demonstrates significant anticancer effects in human malignant mesothelioma.
- Cyclopamine reduces aggressive cancer cell subpopulations, including cancer stem cells.
- This study suggests that targeting hedgehog signaling is a promising therapeutic strategy for malignant mesothelioma.
Related Concept Videos
Hedgehog Signaling Pathway
Hedgehog Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

